Weight-loss injections originally developed for diabetes and obesity treatment are increasingly being marketed to soon-to-be brides and grooms in India, as clinics incorporate the drugs into pre-wedding transformation packages amid rising demand and regulatory scrutiny.

Wellness centres across major cities are promoting such treatments as part of broader grooming services traditionally focused on skincare and styling. A New Delhi-based clinic, Klarity Skin Clinic, advertises a “Mounjaro bride” package combining medication with nutrition plans and exercise routines, reflecting a shift in how pharmaceutical interventions are being positioned in consumer wellness markets.

Doctors say inquiries for these drugs have surged in recent months, particularly among individuals preparing for weddings. Eight physicians interviewed by Reuters reported a noticeable rise in requests from brides and some grooms seeking rapid weight loss ahead of ceremonies, often within fixed timelines.

“Over the last few months, over 20% of the queries we’ve received for obesity injections are from to-be brides, who also openly give us a timeline on how soon they are getting married,” said Rajat Goel, a bariatric surgeon at Hindivine Healthcare in New Delhi. He added that prescriptions were issued only to patients meeting medical criteria, not for purely cosmetic purposes.

The growing interest reflects broader social and cultural dynamics in India, where weddings are often elaborate events shaped by family expectations and social norms. Physical appearance can carry significant weight in arranged marriage settings, contributing to demand for quick and visible results.

Several individuals who spoke to Reuters cited such pressures as a key factor behind their decision to use the drugs. Aditi, a 26-year-old finance professional from Mumbai, said she turned to the medication after conventional methods failed to deliver the desired outcome. She reported losing 10 kilograms before her wedding and said the results improved her confidence during the ceremony.

Others echoed similar motivations. Akshitha, who married last year in Hyderabad, said she opted for injections after struggling to balance fitness routines with wedding preparations. The treatment helped her lose 15 kilograms, bringing her weight to 76 kilograms before the event. She said she may consider using the drugs again after a future pregnancy.

In some cases, the decision has been linked to social stigma. Priya, a 27-year-old technology worker from Bengaluru, said she experienced rejection from prospective grooms’ families due to her weight, prompting her to seek pharmaceutical assistance. She initially used oral semaglutide before switching to injectable medication, losing more than 12 kilograms, though she said her search for a partner continues.

The drugs at the centre of this trend include Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy, both of which entered the Indian market last year. Physicians reported that Mounjaro has become particularly sought after, with demand rising rapidly following its introduction.

Market forecasts reflect the growing interest. India’s obesity drug market is projected to reach approximately 80 billion rupees (about $851.79 million) by 2030, driven by rising awareness, expanding availability, and increasing rates of obesity and related conditions.

Pricing remains a significant factor in accessibility. In India, monthly costs for Mounjaro range from 13,125 rupees for lower doses to 25,781 rupees for higher ones. Wegovy is priced between 5,660 rupees and 16,400 rupees per month, following recent price reductions by Novo Nordisk aimed at improving competitiveness.The market is also becoming more crowded.

Domestic pharmaceutical companies began introducing lower-cost versions of semaglutide-based treatments after the expiration of key patents, expanding access but also raising concerns about oversight and misuse.

India’s drug regulator has responded by increasing surveillance of unauthorized sales and promotional practices, particularly as demand extends beyond medically indicated use. The drugs are approved for individuals classified as obese or overweight with related health conditions such as diabetes, hypertension, or sleep apnea.

Manufacturers have reiterated that the medications should be used strictly under medical supervision. Eli Lilly said Mounjaro is approved only for specific indications and must be administered by qualified healthcare professionals, while Novo Nordisk has discouraged self-medication and off-label use.

Medical experts warn that positioning such treatments as quick solutions for cosmetic goals could undermine patient safety and long-term health outcomes. Dr. Swati Pradhan, founder of Live Light clinic, said she prescribes the injections sparingly and only when patients meet eligibility criteria, emphasizing the importance of sustained lifestyle changes.

The trend comes against a backdrop of rising obesity levels in India. A study published in The Lancet projects that the country could have more than 440 million overweight or obese individuals by 2050, among the highest totals globally. This has created a rapidly expanding market for weight-management solutions, spanning pharmaceuticals, fitness services, and wellness products.

As clinics continue to integrate medical treatments into lifestyle offerings, regulators and healthcare providers face the challenge of balancing expanding access with appropriate safeguards. The intersection of cultural expectations, commercial incentives, and medical innovation is reshaping how weight-loss therapies are perceived and used in one of the world’s fastest-growing healthcare markets.

Novo Nordisk is navigating a shifting global healthcare landscape with confidence, focusing on innovation, capacity expansion, and long-term growth opportunities across international markets despite near-term competitive pressures.

Novo Nordisk has outlined a realistic yet optimistic outlook for its international operations as global markets adjust to increased competition. The company views this phase as part of a natural market evolution.

International markets remain the largest long-term growth engine for Novo Nordisk’s diabetes and weight-management portfolio. Demand for these therapies continues to rise worldwide.

While some countries are seeing new competitors enter following exclusivity changes, overall patient needs remain strong. This creates space for innovation and differentiated products.

Company leadership has emphasized that high historical market share naturally attracts competition. This reflects the strength of Novo Nordisk’s existing product base.

Rather than signaling weakness, competitive entry highlights the maturity and value of the markets Novo Nordisk has helped build. These foundations support sustained demand.

Novo Nordisk operates across more than 80 international markets through well-established local affiliates. This broad presence provides resilience and market insight.

The company remains structurally well positioned outside the United States, with deep regulatory experience and strong healthcare partnerships. These factors support long-term adaptability.

Changes in global obesity treatment markets are creating new dynamics, including easier cross-border access and digital distribution. Novo Nordisk is actively adjusting to these trends.

Innovation remains central to the company’s strategy, with higher-dose formulations and next-generation products in development. These advances aim to strengthen clinical outcomes.

Capacity expansion continues to be a priority as demand for weight-loss and diabetes treatments grows worldwide. Manufacturing investments support consistent global supply.

Novo Nordisk is also focused on improving patient access through education and collaboration with healthcare systems. This reinforces trust and brand leadership.

Competition from global peers is seen as a catalyst for faster innovation across the sector. Patients ultimately benefit from wider therapeutic choices.

The company’s research pipeline supports confidence beyond the near term. Ongoing trials reflect a commitment to science-driven growth.

Leadership has communicated transparently with investors about short-term challenges. This clarity reinforces long-term credibility.

International healthcare demand continues to rise due to aging populations and lifestyle-related conditions. Novo Nordisk remains aligned with these global trends.

Digital health tools and data-driven care models are expanding treatment reach. Novo Nordisk is integrating these approaches into its strategy.

The company’s experience navigating regulatory transitions positions it well for future adjustments. Past adaptability supports confidence going forward.

Market pressures are being met with proactive planning rather than retrenchment. This reflects a forward-looking corporate mindset.

Despite near-term headwinds, long-term volume potential remains substantial across emerging and developed markets alike. Growth fundamentals remain intact.

Novo Nordisk’s focus on quality, innovation, and scale continues to define its global identity. These strengths support sustained leadership.

Overall, the company views current challenges as part of a broader growth cycle. Strategic execution is expected to deliver long-term value.

Pfizer’s strategic move to revise its bid for Metsera underscores its dedication to advancing next-generation obesity therapies and fostering competition in the global pharmaceutical landscape.

In a major development in the global pharmaceutical industry, Pfizer has taken a decisive step to strengthen its position in the race for Metsera, an emerging leader in obesity drug development.

The U.S. pharmaceutical giant announced that it has removed certain conditions from its initial bid, signaling greater flexibility and commitment to finalizing the merger.

This move comes as Pfizer seeks to outpace rival bidder Novo Nordisk, which recently made a competing $10 billion offer for the innovative biotech company.

The decision, revealed in a letter filed in Delaware, highlights Pfizer’s strategic focus on expanding its presence in the fast-growing obesity treatment market—a sector projected to reach over $100 billion by 2030.

By simplifying the terms of its proposal, Pfizer aims to demonstrate its long-term confidence in Metsera’s scientific potential and its readiness to collaborate with the company’s leadership to accelerate groundbreaking metabolic health therapies.

According to Pfizer, the revised proposal eliminates conditions related to direct stock sales and public disclosures, making the acquisition process smoother and more transparent.

The company emphasized that its offer is designed not only to strengthen shareholder value but also to preserve Metsera’s research autonomy and innovative culture.

This approach marks a notable shift toward cooperative growth rather than a traditional corporate takeover.

Pfizer’s renewed commitment comes at a crucial time for the company, which has been strategically realigning its portfolio following the pandemic.

After experiencing fluctuations in COVID-19 vaccine revenues, Pfizer has turned its focus toward high-growth therapeutic areas such as obesity, cardiovascular health, and oncology.

The acquisition of Metsera would represent a major leap in this direction, granting Pfizer access to a promising pipeline of next-generation weight management and metabolic drugs.

Industry analysts view this move as a positive and forward-thinking strategy that positions Pfizer as a serious contender in a market currently dominated by Novo Nordisk and Eli Lilly.

Obesity treatment has rapidly become one of the most dynamic segments in pharmaceuticals, with new drug classes offering not just weight loss benefits but also improved cardiovascular and metabolic outcomes.

Pfizer’s interest in Metsera aligns with its broader mission to develop holistic health solutions that go beyond symptom management and address underlying disease mechanisms.

Beyond business strategy, Pfizer’s pursuit of Metsera also underscores its belief in fostering scientific collaboration and expanding patient access to cutting-edge therapies.

Company representatives have emphasized that their vision for the merger includes leveraging Pfizer’s global scale and regulatory expertise while maintaining Metsera’s innovative research environment.

This synergy could accelerate clinical development timelines and make advanced obesity treatments available to millions worldwide sooner than expected.

While Novo Nordisk’s bid has added competitive tension to the acquisition process, Pfizer’s decision to revise its offer reflects resilience and adaptability—qualities that have long defined the company’s approach to research and partnerships.

Market observers suggest that Pfizer’s proactive adjustments could appeal to Metsera’s board, which is tasked with balancing shareholder value against long-term strategic fit.

If successful, the acquisition could signal a new era of collaboration in obesity research, combining Pfizer’s established global infrastructure with Metsera’s pioneering drug development expertise.

Such a partnership could potentially unlock new treatment options for metabolic diseases that affect more than a billion people globally.

The company’s leadership has reiterated that this move is not merely about expanding Pfizer’s portfolio but about driving positive change in global healthcare.

By focusing on inclusivity, innovation, and scientific excellence, Pfizer hopes to lead the next wave of medical breakthroughs in metabolic health and chronic disease prevention.

As the Delaware court reviews the matter, Pfizer remains optimistic that its revised proposal demonstrates a fair, forward-looking vision for both companies.

The outcome of this bid could redefine the competitive landscape in obesity therapeutics and serve as a case study in how pharmaceutical giants are adapting to meet the evolving needs of patients and markets worldwide.

With this bold and positive move, Pfizer has once again shown that innovation and flexibility remain at the heart of its mission—delivering transformative solutions for patients, shareholders, and the future of global healthcare.